Indofarma Tbk (INAF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indofarma Tbk (INAF) has a cash flow conversion efficiency ratio of 0.024x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp-18.71 Billion ≈ $-1.10 Million USD) by net assets (Rp-788.96 Billion ≈ $-46.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Indofarma Tbk's balance sheet to measure how much of total assets are equity-financed.
Indofarma Tbk - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Indofarma Tbk's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INAF cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Indofarma Tbk Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indofarma Tbk ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pulsenmore Ltd
TA:PULS
|
-0.196x |
|
Andromeda Metals Ltd
AU:ADN
|
-0.013x |
|
Master Pack Group Bhd
KLSE:7029
|
0.021x |
|
Pudjiadi & Sons Tbk
JK:PNSE
|
0.115x |
|
Transtema Group AB
ST:TRANS
|
-0.006x |
|
Mistral Iberia Real Estate SOCIMI S.A.
MC:YMIB
|
-0.026x |
|
Heavy Minerals Ltd
AU:HVY
|
-0.149x |
|
Gryphon Digital Mining Inc.
NASDAQ:GRYP
|
0.080x |
Annual Cash Flow Conversion Efficiency for Indofarma Tbk (2000–2024)
The table below shows the annual cash flow conversion efficiency of Indofarma Tbk from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see INAF market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rp-1.14 Trillion ≈ $-67.04 Million |
Rp-21.65 Billion ≈ $-1.27 Million |
0.019x | -91.99% |
| 2023-12-31 | Rp-804.15 Billion ≈ $-47.12 Million |
Rp-190.10 Billion ≈ $-11.14 Million |
0.236x | +126.88% |
| 2022-12-31 | Rp86.35 Billion ≈ $5.06 Million |
Rp-75.95 Billion ≈ $-4.45 Million |
-0.880x | -581.24% |
| 2021-12-31 | Rp508.31 Billion ≈ $29.78 Million |
Rp92.90 Billion ≈ $5.44 Million |
0.183x | +68.96% |
| 2020-12-31 | Rp430.33 Billion ≈ $25.22 Million |
Rp46.55 Billion ≈ $2.73 Million |
0.108x | +162.70% |
| 2019-12-31 | Rp504.94 Billion ≈ $29.59 Million |
Rp20.79 Billion ≈ $1.22 Million |
0.041x | +129.05% |
| 2018-12-31 | Rp496.65 Billion ≈ $29.10 Million |
Rp-70.39 Billion ≈ $-4.12 Million |
-0.142x | -150.69% |
| 2017-12-31 | Rp526.41 Billion ≈ $30.85 Million |
Rp147.18 Billion ≈ $8.62 Million |
0.280x | +150.63% |
| 2016-12-31 | Rp575.76 Billion ≈ $33.74 Million |
Rp-317.96 Billion ≈ $-18.63 Million |
-0.552x | -343.75% |
| 2015-12-31 | Rp592.71 Billion ≈ $34.73 Million |
Rp134.28 Billion ≈ $7.87 Million |
0.227x | -9.82% |
| 2014-12-31 | Rp591.96 Billion ≈ $34.69 Million |
Rp148.73 Billion ≈ $8.71 Million |
0.251x | +204.81% |
| 2013-12-31 | Rp590.79 Billion ≈ $34.62 Million |
Rp-141.62 Billion ≈ $-8.30 Million |
-0.240x | -280.88% |
| 2012-12-31 | Rp650.10 Billion ≈ $38.09 Million |
Rp-40.91 Billion ≈ $-2.40 Million |
-0.063x | -230.42% |
| 2011-12-31 | Rp609.19 Billion ≈ $35.70 Million |
Rp29.40 Billion ≈ $1.72 Million |
0.048x | -36.66% |
| 2010-12-31 | Rp311.27 Billion ≈ $18.24 Million |
Rp23.71 Billion ≈ $1.39 Million |
0.076x | -43.89% |
| 2009-12-31 | Rp298.72 Billion ≈ $17.50 Million |
Rp40.56 Billion ≈ $2.38 Million |
0.136x | +121.50% |
| 2008-12-31 | Rp296.60 Billion ≈ $17.38 Million |
Rp-187.31 Billion ≈ $-10.98 Million |
-0.632x | -320.73% |
| 2007-12-31 | Rp291.56 Billion ≈ $17.08 Million |
Rp83.42 Billion ≈ $4.89 Million |
0.286x | +9.70% |
| 2006-12-31 | Rp280.49 Billion ≈ $16.44 Million |
Rp73.15 Billion ≈ $4.29 Million |
0.261x | +226.07% |
| 2005-12-31 | Rp265.25 Billion ≈ $15.54 Million |
Rp-54.87 Billion ≈ $-3.22 Million |
-0.207x | -133.21% |
| 2004-12-31 | Rp255.67 Billion ≈ $14.98 Million |
Rp159.25 Billion ≈ $9.33 Million |
0.623x | +310.06% |
| 2003-12-31 | Rp267.94 Billion ≈ $15.70 Million |
Rp40.70 Billion ≈ $2.39 Million |
0.152x | +64.33% |
| 2000-12-31 | Rp292.57 Billion ≈ $17.14 Million |
Rp27.05 Billion ≈ $1.58 Million |
0.092x | -- |
About Indofarma Tbk
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutic… Read more